New York, N.Y., June 22, 2022 – Pfizer Inc. (NYSE:PFE) – On March 14, we announced that, effective immediately, Pfizer would donate the equivalent of all profits from our sales in Russia to causes that provide direct humanitarian support to the people of Ukraine. Today, I am pleased to say we are making good on this promise.
NEW YORK and MAINZ, GERMANY, June 15, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the European Medicines Agency (EMA) has initiated a rolling review for a variant-adapted version of the companies’ COVID-19 vaccine. This rolling review is initially based on chemistry, manufacturing, and controls (CMC) data shared with EMA earlier this month. As clinical data become available, including data on immunogenicity against Omicron and its subvariants, it will be added to the rolling submission.
Pfizer Inc. (NASDAQ:PFE), MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ:MOR), and Incyte (NASDAQ:INCY) today announced a clinical trial collaboration and supply agreement to investigate the immunotherapeutic combination of Pfizer’s TTI-622, a novel SIRPα-Fc fusion protein, and Monjuvi® (tafasitamab-cxix) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).
For Immediate Release-LAKE FOREST, IL., February 23, 2018 - Hospira, Inc., a Pfizer company, is voluntarily recalling 3 lots of Labetalol Hydrochloride Injection, USP, 100 mg/20 mL Vial (NDC 0409-2267-20), and one lot of Labetalol Hydrochloride Injection, USP, Novaplus® (NDC 0409-2267-25) to the hospital/institution level. Hospira, Inc. initiated this recall due to the discovery of cracks on the rim surface of vials for these lots, which is covered by the stopper and crimp seal. Cracked vials may result in a lack of sterility assurance for the product.
For Immediate Release-LAKE FOREST, IL., March 05, 2018 - Hospira, Inc., a Pfizer company, is voluntarily recalling three lots of Hydromorphone HCl Injection, USP CII 10 mg/mL, 1 mL in 2 mL Single Dose Vials lot numbers 71330DD (NDC 0409-2634-01), and 691853F and 700753F (NDC 0703-0110-01 – Teva lots) to the hospital/institution level. Hospira, Inc. initiated this recall on February 07, 2018 due to the potential that units from these lots may be empty or cracked at the bottom of the glass vial.
NEW YORK, N.Y., April 30 - Pfizer Inc. (NYSE:PFE) today announced that Dawn Rogers will become Executive Vice President of Worldwide Human Resources, effective June 1, 2018. She is currently Senior Vice President of Human Resources for the Chief Operating Officer, Albert Bourla. Ms. Rogers will report directly to Chairman and CEO Ian Read and join Pfizer’s Executive Leadership team.
Meridian, a subsidiary of Pfizer that manufactures EpiPen auto-injectors, has experienced intermittent constraints affecting U.S. supply. The U.S. Food and Drug Administration (FDA) has posted a supply notification on its website about EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors, and the authorized generic versions of these strengths, to provide greater transparency and confirm that the product remains available.
NEW YORK, N.Y., May 24 – Pfizer Inc. today announced that it has reached a settlement agreement with the federal government to resolve civil claims relating to certain financial donations made by the Company to independent charity patient assistance programs prior to 2017. Under the agreement, Pfizer will make a payment of $23.85 million to the government to resolve these claims.
FOR IMMEDIATE RELEASE-LAKE FOREST, IL., June 4, 2018 - Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.
NEW YORK, NY, September 17, 2019 - Football legend Terry Bradshaw and Pfizer are partnering for a second year on the All About Your Boom™ campaign with the goal of educating Baby Boomers about the risk for pneumococcal pneumonia. The campaign encourages adults aged 65 or older to speak with their healthcare provider about whether vaccination to help prevent pneumococcal pneumonia is right for them.